Management of transthyretin amyloidosis.

Details

Ressource 1Download: Condolucci_SMW_2021.pdf (4768.85 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-SA 4.0
Serval ID
serval:BIB_1ADB98786F3C
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Management of transthyretin amyloidosis.
Journal
Swiss medical weekly
Author(s)
Condoluci A., Théaudin M., Schwotzer R., Pazhenkottil A.P., Arosio P., Averaimo M., Bacher U., Bode P., Cavalli A., Dirnhofer S., Djerbi N., Dobner S., Fehr T., Garofalo M., Gaspert A., Gerull S., Heimgartner R., Hübers A., Jung H.H., Kessler C., Knöpfel R., Laptseva N., Magini G., Manka R., Mazzucchelli L., Meyer M., Mihaylova V., Monney P., Mylonas A., Nkoulou R., Pabst T., Pfister O., Rüfer A., Schmidt A., Seeger H., Stämpfli S.F., Stirnimann G., Suter T., Treglia G., Tzankov A., Vetter F., Zweier M., Flammer A.J., Gerber B.
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Publication state
Published
Issued date
11/10/2021
Peer-reviewed
Oui
Volume
151
Pages
w30053
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Transthyretin amyloidosis (ATTR amyloidosis) is a disease caused by deposition of transthyretin fibrils in organs and tissues, which causes their dysfunction. The clinical heterogeneity of ATTR amyloidosis and the variable presentation of symptoms at early disease stages, historically meant treatment delays. Diagnostic tools and therapy options of ATTR amyloidosis have markedly improved in recent years. The first Swiss Amyloidosis Network (SAN) meeting (Zurich, Switzerland, January 2020) aimed to define a consensus statement regarding the diagnostic work-up and treatment for systemic amyloidosis, tailored to the Swiss healthcare system. A consortium of 45 clinicians and researchers from all Swiss regions and universities was selected by the SAN committee to represent all sub-specialty groups involved in care of patients with amyloidosis. A steering committee conducted the literature search and analysis, wrote the critical synthesis and elaborated a list of statements that were evaluated by all the participants. These recommendations will improve outcomes and quality of life for patients with ATTR amyloidosis. A global review of these guidelines is planned every 3 years with a formal meeting of all the involved experts.
Pubmed
Open Access
Yes
Create date
06/11/2021 16:58
Last modification date
13/08/2022 6:08
Usage data